Type 2 diabetes is now a global epidemic. However, drugs to treat diabetes are inadequate and generally have dose limiting side effects. We seek to address the epidemic with superior drugs based on a better understanding of the disease.
 
  MBX-102   MBX-8025   MBX-2044   MBX-2982   Additional Programs  
  Home > Pipeline > MBX-2044  
A Next-Generation Insulin Sensitizer
MBX-2044 is our follow-on compound to MBX-102, and like MBX-102, it is being developed as an effective insulin sensitizer that is not associated with edema or weight gain.
Results from a completed Phase 2a study of MBX-2044 showed it to be safe and well-tolerated across a broad dose range. We believe MBX-2044 has a similar profile to MBX-102 but is more potent. As a result, MBX-2044 may produce the same efficacy as MBX-102 at a lower dose.